These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 25426699)
41. [Prophylaxis of pertussis: development and use of acellular pertussis vaccine]. Chuprinina RP; Alekseeva IA; Ozeretskovskiĭ NA Zh Mikrobiol Epidemiol Immunobiol; 2006; (1):99-105. PubMed ID: 16532655 [TBL] [Abstract][Full Text] [Related]
42. [Pertussis vaccine for adolescents and adults]. Perret P C Rev Chilena Infectol; 2006 Sep; 23(3):257-60. PubMed ID: 16896501 [TBL] [Abstract][Full Text] [Related]
43. Which strategy for pertussis vaccination today? Girard DZ Paediatr Drugs; 2002; 4(5):299-313. PubMed ID: 11994035 [TBL] [Abstract][Full Text] [Related]
48. Prevention of pertussis: An unresolved problem. Esposito S; Principi N Hum Vaccin Immunother; 2018; 14(10):2452-2459. PubMed ID: 29856680 [TBL] [Abstract][Full Text] [Related]
49. Priming with whole-cell versus acellular pertussis vaccine. Liko J; Robison SG; Cieslak PR N Engl J Med; 2013 Feb; 368(6):581-2. PubMed ID: 23388023 [No Abstract] [Full Text] [Related]
50. Pertussis vaccines and the challenge of inducing durable immunity. Warfel JM; Edwards KM Curr Opin Immunol; 2015 Aug; 35():48-54. PubMed ID: 26091979 [TBL] [Abstract][Full Text] [Related]
51. Clinical trials of acellular pertussis vaccine in Sweden. An attempt to solve the problem of pertussis vaccination. Olin P Ann Sclavo Collana Monogr; 1986; 3(1-2):165-72. PubMed ID: 2892504 [No Abstract] [Full Text] [Related]
52. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641 [TBL] [Abstract][Full Text] [Related]
53. The effect of pertussis whole cell and acellular vaccines on pulmonary immunology in an aerosol challenge model. Carter CR; Dagg BM; Whitmore KM; Keeble JR; Asokanathan C; Xing D; Walker KB Cell Immunol; 2004 Jan; 227(1):51-8. PubMed ID: 15051514 [TBL] [Abstract][Full Text] [Related]
54. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Juretzko P; von Kries R; Hermann M; Wirsing von König CH; Weil J; Giani G Clin Infect Dis; 2002 Jul; 35(2):162-7. PubMed ID: 12087522 [TBL] [Abstract][Full Text] [Related]
55. Re-emergence of pertussis: what are the solutions? Libster R; Edwards KM Expert Rev Vaccines; 2012 Nov; 11(11):1331-46. PubMed ID: 23249233 [TBL] [Abstract][Full Text] [Related]
56. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705 [TBL] [Abstract][Full Text] [Related]
57. T-cell immune responses to Bordetella pertussis infection and vaccination. Fedele G; Cassone A; Ausiello CM Pathog Dis; 2015 Oct; 73(7):. PubMed ID: 26242279 [TBL] [Abstract][Full Text] [Related]
59. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Witt MA; Arias L; Katz PH; Truong ET; Witt DJ Clin Infect Dis; 2013 May; 56(9):1248-54. PubMed ID: 23487373 [TBL] [Abstract][Full Text] [Related]
60. Acellular pertussis vaccines and pertussis resurgence: revise or replace? Ausiello CM; Cassone A mBio; 2014 Jun; 5(3):e01339-14. PubMed ID: 24917600 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]